Molecular Mechanisms and Therapeutics in Hemorrhagic Shock

Dear Colleagues,

Hemorrhagic shock, a severe form of hypovolemic shock resulting from significant blood loss, poses a substantial global health burden with high mortality rates. Despite well-established medical interventions, trauma-related hemorrhagic shock has resulted in the loss of more than 75 million lives globally among young individuals. Beyond the cessation of bleeding, hemorrhagic shock progressed into a state of hypoperfusion-induced hypoxia, exacerbating tissue damage and systemic ischemia-reperfusion injury upon subsequent fluid resuscitation. This cascade of events triggers the release of inflammatory cytokines, initiating an inflammatory response that contributes to multi-organ dysfunction or even failure. Consequently, survivors of trauma-induced hemorrhage often face diminished functional outcomes and increased long-term mortality due to the lingering effects of this inflammatory response. Despite significant efforts to understand the pathogenesis of hemorrhagic shock, precise molecular mechanisms and effective treatments remain elusive. This Special Issue titled “Molecular Mechanisms and Therapeutics in Hemorrhagic Shock”, curated by Dr. Jacob, aims to shed light on the intricate molecular mechanism underlying the pathogenesis of hemorrhagic shock and explore potential therapeutic interventions. The scope of research covered in this Special Issue encompasses various organs affected by hemorrhagic shock, including the heart, lungs, liver, and kidneys. By collating contributions from diverse researchers, this Special Issue aims to foster a deeper understanding of hemorrhagic shock pathophysiology and facilitate the development of targeted therapeutic approaches to mitigate its devastating effects.

Dr. Asha Jacob
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hemorrhagic shock
• trauma-induced hemorrhage
• ischemia-reperfusion injury
• immune response
• shock therapeutics and their mechanisms
• systemic inflammatory response
• multi-organ dysfunction
• tissue damage
• organ injury
• mitochondrial dysfunction